Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Joao Siffert"'
Autor:
Raymond T. Bartus, Lamar Brown, Alistair Wilson, Brian Kruegel, Joao Siffert, Eugene M. Johnson, Jr., Jeffrey H. Kordower, Christopher D. Herzog
Publikováno v:
Neurobiology of Disease, Vol 44, Iss 1, Pp 38-52 (2011)
Recent analyses of autopsied brains from subjects previously administered AAV2-neurturin (NRTN) gene transfer argues that optimizing the effects of neurotrophic factors in Parkinson's disease (PD) likely requires delivery to both the degenerating cel
Externí odkaz:
https://doaj.org/article/4228d242ea2a440d88692a26d14c70a3
Autor:
Joao Siffert, Stewart J. Tepper, Paul Winner, Peter McAllister, Rashmi B. Halker, Stephen D. Silberstein, Ramy A. Mahmoud
Publikováno v:
Headache: The Journal of Head and Face Pain. 57:862-876
Objective To further characterize the clinical utility of AVP-825 based on additional prespecified outcomes and post hoc analyses of COMPASS, a Phase 3 comparative efficacy trial of AVP-825 vs 100 mg oral sumatriptan (NCT01667679). AVP-825 was approv
Autor:
Nadine Knowles, John G. Nutt, Laura E. Pope, Stewart A. Factor, Anthony E. Lang, Joao Siffert, Susan H. Fox, Leonard Verhagen Metman, Matthew Brodsky
Publikováno v:
Movement Disorders. 32:893-903
Background: Nondopaminergic pathways represent potential targets to treat levodopa-induced dyskinesia in Parkinson's disease (PD). This pilot-study (NCT01767129) examined the safety/efficacy of the sigma-1 receptor-agonist and glutamatergic/monoamine
Publikováno v:
Pharmacology & Therapeutics. 164:170-182
Dextromethorphan (DM) has been used for more than 50years as an over-the-counter antitussive. Studies have revealed a complex pharmacology of DM with mechanisms beyond blockade of N-methyl-d-aspartate (NMDA) receptors and inhibition of glutamate exci
Autor:
Robert A. Rissman, Michael S. Rafii, Paul S. Aisen, Joao Siffert, James B. Brewer, Mark H. Tuszynski, Ronald G. Thomas, David Barba
Publikováno v:
JAMA neurology. 75(7)
Importance Nerve growth factor (NGF) is an endogenous neurotrophic factor that prevents the death and augments the functional state of cholinergic neurons of the basal forebrain, a cell population that undergoes extensive degeneration in Alzheimer di
Autor:
Fred Ledon, Andrea E. Formella, Charles S. Davis, Richard D. Zorowitz, Joao Siffert, David N. Alexander
Publikováno v:
PMR : the journal of injury, function, and rehabilitation.
Dextromethorphan (DM) / quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based on efficacy and safety trials in patients with PBA caused by amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PB
Autor:
Charles Yonan, Charles S. Davis, Joao Siffert, Andrew J. Cutler, Fred Ledon, Rachelle S. Doody, Stephen D'Amico, Paul Shin
Publikováno v:
CNS Spectrums. 21:450-459
BackgroundDextromethorphan (DM)/quinidine (Q) is an approved treatment for pseudobulbar affect (PBA) based on trials in amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness and tolerability for PBA secondary to d
Autor:
Joao Siffert, Stewart J. Tepper, Stephen D. Silberstein, Roger Cady, John C. Messina, Ramy A. Mahmoud, Per Gisle Djupesland, Paul Shin
Publikováno v:
Headache: The Journal of Head and Face Pain. 55:621-635
Objective The objective of this study was to compare the efficacy, tolerability, and safety of AVP-825, an investigational bi-directional breath-powered intranasal delivery system containing low-dose (22 mg) sumatriptan powder, vs 100 mg oral sumatri
Autor:
Mark Stacy, Raymond T. Bartus, Joao Siffert, Ron L. Alterman, Andres M. Lozano, Christopher D. Herzog, C. Warren Olanow, Dennis A. Turner, Nicholas M. Boulis, Anthony E. Lang, Tiffany L. Baumann
Publikováno v:
Neurology. 80:1698-1701
Objective: In an effort to account for deficiencies in axonal transport that limit the effectiveness of neurotrophic factors, this study tested the safety and feasibility, in moderately advanced Parkinson disease (PD), of bilaterally administering th
Autor:
Stephen, Silberstein, Paul K, Winner, Peter J, McAllister, Stewart J, Tepper, Rashmi, Halker, Ramy A, Mahmoud, Joao, Siffert
Publikováno v:
Headache. 57(6)
To further characterize the clinical utility of AVP-825 based on additional prespecified outcomes and post hoc analyses of COMPASS, a Phase 3 comparative efficacy trial of AVP-825 vs 100 mg oral sumatriptan (NCT01667679). AVP-825 was approved in Janu